VBI Vaccines Inc. (VBIV) Earns Buy Rating from Analysts at Ladenburg Thalmann
Equities researchers at Ladenburg Thalmann began coverage on shares of VBI Vaccines Inc. (NASDAQ:VBIV) in a report released on Tuesday. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.
VBI Vaccines (NASDAQ:VBIV) traded down 4.20% on Tuesday, hitting $3.19. 48,009 shares of the company traded hands. VBI Vaccines has a 12 month low of $3.07 and a 12 month high of $4.40. The stock’s market cap is $115.26 million. The stock’s 50-day moving average is $3.70 and its 200 day moving average is $3.83.
A number of hedge funds and other institutional investors have recently bought and sold shares of VBIV. Cambridge Investment Research Advisors Inc. acquired a new position in VBI Vaccines during the fourth quarter worth approximately $3,497,000. Hudson Bay Capital Management LP acquired a new position in VBI Vaccines during the first quarter worth approximately $2,338,000. Vanguard Group Inc. raised its position in VBI Vaccines by 2,094.1% in the second quarter. Vanguard Group Inc. now owns 358,275 shares of the biopharmaceutical company’s stock worth $1,415,000 after buying an additional 341,946 shares in the last quarter. Finally, BlackRock Fund Advisors raised its position in VBI Vaccines by 1,701.6% in the second quarter. BlackRock Fund Advisors now owns 44,789 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 42,303 shares in the last quarter. Institutional investors own 12.26% of the company’s stock.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/09/vbi-vaccines-inc-vbiv-earns-buy-rating-from-analysts-at-ladenburg-thalmann.html
About VBI Vaccines
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with MarketBeat.com's FREE daily email newsletter.